Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop after the U.S. Department of Health and Human Services announced a new kidney care strategy. The federal plan aims to increase competition and reduce dominance in the dialysis market, which negatively impacted DaVita's shares. Investors affected by this may join a class action lawsuit. This investigation highlights regulatory risks for companies in the healthcare sector amid policy changes.
DaVita Inc shares are trading at USD 190.01 on Pluang as of Oct 29, 2026 20:31 WIB, showing a 1-day gain of 3.31%. The stock's market cap stands at $11.73 billion with a volume of 439,066. Investors on Pluang hold the stock for an average of 116 days, reflecting steady interest despite recent regulatory concerns.
